167 results
424B3
SYRE
Spyre Therapeutics Inc.
15 May 24
Prospectus supplement
4:06pm
Stock from the Amended and Restated Spyre 2023 Equity Incentive Plan (the “Asset Acquisition”). The Common Stock and Series A Preferred Stock related … Annual Meeting.
8. Stock-Based Compensation
2015 Equity Incentive Plan
In March 2015, the Company adopted the 2015 Equity Incentive Plan (“2015 Plan
8-K
SYRE
Spyre Therapeutics Inc.
15 May 24
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
7:40am
(“Common Stock”), with an aggregate grant date value of $700,000 under the Company’s 2016 Equity Incentive Plan, as amended and restated
POS AM
wfbuf
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
424B3
twpjtq5sm2e5bn
18 Mar 24
Prospectus supplement
4:06pm
8-K
EX-10.1
qdrem ozvy7oi2dejyu
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
POS AM
tf7y38wrry
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
POS AM
o8fstqial7u2g
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
S-8
c4hdzpwwb6
29 Feb 24
Registration of securities for employees
5:06pm
S-8
EX-5.1
df9sspviofr7lpnlg
29 Feb 24
Registration of securities for employees
5:06pm
S-8
d7w1i392ebodn
29 Feb 24
Registration of securities for employees
5:06pm